Evaluating Pioglitazone for Managing Type 2 Diabetes Mellitus in Patients with Nonalcoholic Fatty Liver Disease.

Vijay Panikar; Apoorva Gupta; Nikhil Nasikkar; Shashank Joshi; Sanhita Walwalkar; Ishita Sachdev; Mangesh Tiwaskar; Krish Panikar; Aditi Mahajan -; Narayan Deogaonkar; Jimit Vadgama; Harshpreet Tuteja; Divya Lalwani; Samiksha Singh; Parveen Kader

doi:10.59556/japi.73.1250

November 1, 2025

Evaluating Pioglitazone for Managing Type 2 Diabetes Mellitus in Patients with Nonalcoholic Fatty Liver Disease.

View Full Paper

Ask AI

Bookmark

Share

Key Points

Glycemic control improves in T2DM patients with NAFLD when treated with pioglitazone, reducing fatty liver grades.
Key evidence indicates a reduction in both fibrosis stages and fatty liver grades with pioglitazone treatment.
Assessment of diabetes management using pioglitazone focused on improved health markers related to liver function.
This treatment may enhance overall metabolic health in individuals with combined T2DM and NAFLD.

Implication

Observational analysis shows improved glycemic control in T2DM patients with NAFLD using pioglitazone, suggesting potential benefits for liver health.

Abstract

In T2DM patients with NAFLD, pioglitazone improves glycemic control and reduces both fatty liver grades and fibrosis stages.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Panikar et al. (2025) studied this question.

synapsesocial.com/papers/6928f106a65b730b9ea79d05 https://doi.org/10.59556/japi.73.1250

View Full Paper

Ask AI

Bookmark

Share

Evaluating Pioglitazone for Managing Type 2 Diabetes Mellitus in Patients with Nonalcoholic Fatty Liver Disease.

Key Points

Implication

Abstract

Discussion

Cite This Study

Evaluating Pioglitazone for Managing Type 2 Diabetes Mellitus in Patients with Nonalcoholic Fatty Liver Disease.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading